CN117545738A - 1-[1-(4-苄氧基-3,5-二氟-苯甲酰基)-4-氟-吡咯烷-2-羰基]吡咯烷-2-腈 - Google Patents

1-[1-(4-苄氧基-3,5-二氟-苯甲酰基)-4-氟-吡咯烷-2-羰基]吡咯烷-2-腈 Download PDF

Info

Publication number
CN117545738A
CN117545738A CN202180047448.7A CN202180047448A CN117545738A CN 117545738 A CN117545738 A CN 117545738A CN 202180047448 A CN202180047448 A CN 202180047448A CN 117545738 A CN117545738 A CN 117545738A
Authority
CN
China
Prior art keywords
compound
formula
disease
pyrrolidine
benzyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180047448.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·塔拉戈克鲁亚
R·普拉德斯科萨诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankerui Treatment Co
Original Assignee
Ankerui Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankerui Treatment Co filed Critical Ankerui Treatment Co
Publication of CN117545738A publication Critical patent/CN117545738A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN202180047448.7A 2020-07-07 2021-07-06 1-[1-(4-苄氧基-3,5-二氟-苯甲酰基)-4-氟-吡咯烷-2-羰基]吡咯烷-2-腈 Pending CN117545738A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382606.0 2020-07-07
EP20382606 2020-07-07
PCT/EP2021/068577 WO2022008477A1 (en) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Publications (1)

Publication Number Publication Date
CN117545738A true CN117545738A (zh) 2024-02-09

Family

ID=71607883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047448.7A Pending CN117545738A (zh) 2020-07-07 2021-07-06 1-[1-(4-苄氧基-3,5-二氟-苯甲酰基)-4-氟-吡咯烷-2-羰基]吡咯烷-2-腈

Country Status (19)

Country Link
US (1) US12459891B2 (enExample)
EP (1) EP4178945B1 (enExample)
JP (1) JP7628716B2 (enExample)
KR (1) KR20230035604A (enExample)
CN (1) CN117545738A (enExample)
AU (1) AU2021303440A1 (enExample)
BR (1) BR112023000335A2 (enExample)
CA (1) CA3185064A1 (enExample)
ES (1) ES2997164T3 (enExample)
HR (1) HRP20241527T1 (enExample)
HU (1) HUE068953T2 (enExample)
IL (1) IL299035B1 (enExample)
MA (1) MA60250B1 (enExample)
MX (1) MX2023000261A (enExample)
RS (1) RS66215B1 (enExample)
SM (1) SMT202400460T1 (enExample)
TW (1) TWI893162B (enExample)
WO (1) WO2022008477A1 (enExample)
ZA (1) ZA202213708B (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104903314A (zh) * 2012-11-12 2015-09-09 巴塞罗纳大学 1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
WO2005027934A1 (ja) 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104903314A (zh) * 2012-11-12 2015-09-09 巴塞罗纳大学 1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROGER PRADES，ET AL.: ""The prolyloligopeptidaseinhibitorIPR19 amelioratescognitivedeficits inmouse models ofschizophrenia"", 《EUROPEAN NEUROPSYCHOPHARMACOLOGY》, vol. 27, 31 December 2017 (2017-12-31), pages 180 - 191 *
王若松: "《静脉麻醉与药物输注学》", vol. 1, 31 October 2001, 人民军医出版社, pages: 18 - 19 *

Also Published As

Publication number Publication date
ZA202213708B (en) 2024-04-24
IL299035A (en) 2023-02-01
TWI893162B (zh) 2025-08-11
JP7628716B2 (ja) 2025-02-12
SMT202400460T1 (it) 2025-01-14
EP4178945B1 (en) 2024-08-28
BR112023000335A2 (pt) 2023-01-31
US12459891B2 (en) 2025-11-04
AU2021303440A1 (en) 2023-02-02
EP4178945C0 (en) 2024-08-28
US20230250058A1 (en) 2023-08-10
WO2022008477A1 (en) 2022-01-13
ES2997164T3 (en) 2025-02-14
EP4178945A1 (en) 2023-05-17
CA3185064A1 (en) 2022-01-13
HUE068953T2 (hu) 2025-02-28
MX2023000261A (es) 2023-04-13
JP2023533932A (ja) 2023-08-07
MA60250B1 (fr) 2024-11-29
TW202216689A (zh) 2022-05-01
KR20230035604A (ko) 2023-03-14
HRP20241527T1 (hr) 2025-01-03
IL299035B1 (en) 2026-03-01
RS66215B1 (sr) 2024-12-31

Similar Documents

Publication Publication Date Title
US10611727B2 (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
JP2025097980A (ja) 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
AU2015207867A1 (en) Compounds and methods for the treatment of pain and other diseases
Cacciatore et al. Development of glycine-α-methyl-proline-containing tripeptides with neuroprotective properties
RU2841064C1 (ru) 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил
TWI893162B (zh) 1-[1-(4-苄氧基-3,5-二氟-苯甲醯)-4-氟-吡咯烷-2-羰基]-吡咯烷-2-腈
JP2012521346A (ja) アルツハイマー病の治療のための化合物および方法
US20230174582A1 (en) Vipr2 antagonist peptide
HK40084881B (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40084881A (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
WO2010133000A1 (en) Selective caspase inhibitors and uses thereof
US20060036073A1 (en) Neurotrophic and neuroprotective peptides
HK1214597B (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
WO2008083543A1 (fr) Composés modifiés hétérocycliques contenant de l'azote et leurs utilisations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination